Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00000721 | An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive | PHASE1 | COMPLETED | 85 | — | — | - | Mar 1, 1991 | Oct 28, 2021 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| CD4 Antigens | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Nystatin or clotrimazole for suppression of oral thrush. * Aerosolized pentamidine for Pneumocystis prophylaxis in Group A patients. * Trimethoprim / sulfamethoxazole for Pneumocystis prophylaxis in patients who are hematologically stable on tr...